Scopus BioPharma’s Subsidiary — Duet Therapeutics — to Present at the 14th Annual RNA Consortium Meeting
September 03 2021 - 9:25AM
Scopus BioPharma Inc. (Nasdaq:
“SCPS”), a clinical-stage biopharmaceutical company
developing transformational therapeutics for serious diseases with
significant unmet medical need, today announced that Alan Horsager,
Ph.D., President and Chief Executive Officer of Duet Therapeutics,
will present at the 14th Annual RNA Consortium Meeting, to be held
virtually on Friday, September 10, 2021.
Duet Therapeutics is a wholly-owned subsidiary
of Scopus. Dr. Horsager is also President — Immuno-Oncology of
Scopus.
Dr. Horsager’s presentation will be part of the
Clinical Translation of Oligonucleotide Therapeutics session. Dr.
Horsager will present on Clinical Development of CpG-STAT3
Inhibitors.
Duet Therapeutics was recently launched by
Scopus BioPharma to integrate the immunotherapy assets of Scopus
and Olimmune, creating the Duet Platform. The Duet Platform is
comprised of three distinctive complementary CpG-STAT3
inhibitors:
• |
RNA silencing |
CpG-STAT3siRNA |
(“DUET-01”) |
• |
Antisense |
CpG-STAT3ASO |
(“DUET-02”) |
• |
DNA-binding inhibitor |
CpG-STAT3decoy |
(“DUET-03”) |
The Duet Platform enables and facilitates development of STAT3
inhibitors which are highly selective for a multitude of different
solid tumors and hematological malignancies. Current and potential
indications for the Duet Platform include: B-cell non-Hodgkin
lymphoma, T-cell non-Hodgkin lymphoma, genitourinary (e.g.,
prostate, kidney and bladder) and head & neck cancers. Duet’s
CpG-STAT3 inhibitors are also being evaluated as combination
therapies with checkpoint inhibitors and CAR-Ts.
About Scopus BioPharma
Scopus BioPharma Inc., both directly and through
subsidiaries, is a clinical-stage biopharmaceutical company
developing transformational therapeutics for serious diseases with
significant unmet medical need. The company’s lead drug candidate
is a novel, targeted immuno-oncology RNA therapy for the treatment
of multiple cancers. This drug candidate is highly distinctive,
encompassing both RNA therapy and immunotherapy by synthetically
linking siRNA to an oligonucleotide TLR9 agonist, creating the
potential for targeted gene silencing with simultaneous TLR
stimulation and immune activation in the tumor microenvironment.
Additional STAT3-targeting immunotherapy drug candidates include
bi-functional antisense and protein degradation therapies. In
addition, the company is developing additional drug candidates that
target the endocannabinoid system, including MRI-1867 for the
treatment systemic sclerosis. The company also seeks to identify
additional compelling technologies for potential acquisition,
in-licensing and/or other similar transactions. Receive updates by
following Scopus BioPharma on Twitter here.
Forward-Looking Statements
This press release may include forward-looking
statements that involve risks and uncertainties. Forward-looking
statements are statements that are not historical facts. Such
forward-looking statements are subject to risks (including those
set forth in the company’s Form 10-K for the fiscal year ended
December 31, 2020, as amended, filed with the U.S. Securities and
Exchange Commission (“SEC”)) and uncertainties which could cause
actual results to differ from the forward-looking statements. The
company expressly disclaims any obligations or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in the company’s
expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.
Investors should realize that if our underlying assumptions for the
projections contained herein prove inaccurate or that known or
unknown risks or uncertainties materialize, actual results could
vary materially from our expectations and projections. Further,
there can be no assurance that the company will identify and/or
consummate any transaction relating to any additional
technologies.
Contacts
Rodd Leeds/David WaldmanCrescendo
Communications, LLCTel: (212) 671-1020Email:
SCPS@crescendo-ir.com
Hugh Burns/Delia Cannan/Nicholas LeasureReevemarkTel: (212)
433-4600Email: scopus@reevemark.com
Scopus BioPharma (NASDAQ:SCPS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scopus BioPharma (NASDAQ:SCPS)
Historical Stock Chart
From Jul 2023 to Jul 2024